Molecular diagnosis system’Exy Station’ is also listed
viewer
Bioneer (064550)Announced on the 25th that the’Accupower HBV quantitative analysis kit’, which quantitatively analyzes the hepatitis B virus, and the molecular diagnosis system’Exy Station’ were listed on the purchase list of the global fund.
Global Fund is a non-profit international organization that has participated by countries and private companies from all over the world to combat diseases such as AIDS, tuberculosis, and malaria in developing countries. Only products whose excellence has been confirmed through rigorous screening and review through a professional judging committee are listed on the purchase list.
Previously, Bioneer was the first Korean company to list the AIDS and hepatitis C virus quantitative analysis kit and Exy Station on the purchase list of the global fund. This time, the HBV quantitative analysis kit was also named.
Hepatitis B is treated by taking drugs that reduce the viral DNA. There are only a few cases of cure, and patients should undergo molecular diagnostic tests on a regular basis. This is because if the amount of viral DNA increases, the probability of developing liver cancer or cirrhosis increases, so it is necessary to measure it quantitatively. According to the World Health Organization (WHO), it is estimated that 2 billion people, or 1 in 4 people in the world, are carriers of hepatitis B.
The HBV quantitative analysis kit released by Bioneer can be a great help in the treatment of hepatitis B because it can measure the level of viral DNA in the blood in a delicate and accurate manner. The company believes that it will be able to close the global health gap and contribute to improving public health by being listed on the global fund purchase list.
Bioneer expects continued sales growth as its molecular diagnostic system Exy Station has been listed on the global fund purchase list for the third consecutive time. Following the spread of Exy Station around the world with the Corona 19 incident, it is expected that this listing will be able to open up a new overseas market as well. It is another way for Bioneer to continue supplying more than 40 types of diagnostic kits optimized for its molecular diagnostic equipment.
Park Han-oh, CEO of Bioneer, said, “The only companies in the world that have listed both the molecular diagnosis system and the AIDS, hepatitis B and hepatitis C molecular diagnostic kits on the global fund purchase list are Abbott, Qiagen, Roche, and Bioneer.” This is a passage that shows that Bioneer has the world’s leading molecular diagnostic technology.” He said, “We will continue to release products that can contribute to the improvement of global health based on 200 proprietary technologies.”
Meanwhile, Bioneer is currently exporting molecular diagnostic equipment and kits to more than 90 countries that can quickly and accurately check whether the new coronavirus (Corona 19) has been infected.
/ Reporter Kim Seong-won [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >